AIMT Aimmune Therapeutics Inc.

26.02
+0.46  (2%)
Previous Close 25.56
Open 25.90
Price To book 5.55
Market Cap 1314921663
Shares 50,535,037
Volume 237,128
Short Ratio 15.33
Av. Daily Volume 293,441

SEC filingsSee all SEC filings

  1. 8-K - Current report 171138966
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015047
  3. 8-K - Current report 171014863
  4. 8-K - Current report 17916872
  5. 8-K - Current report 17874181

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 enrollment has commenced - noted July 5, 2017.
AR101 ARTEMIS
Peanut Allergy
Phase 3 enrollment to be initiation announced May 11, 2017.
AR101 RAMSES
Peanut Allergy
Phase 3 initiated January 2016. Enrollment completion announced November 28, 2016. Top-line data due 1Q 2018.
AR101
Peanut Allergy

Latest News

  1. [$$] Aimmune, DBV: Fighting Over More Than Peanuts
  2. Aimmune teams with Regeneron, Sanofi on peanut allergy drug
  3. Aimmune Therapeutics Announces Clinical Collaboration to Study AR101 with Regeneron and Sanofi’s Dupilumab for Peanut Allergy
  4. Drugmakers Are Planning to Start a Phase 2 Trial to Cure Peanut Allergy
  5. Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?
  6. Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher
  7. Aimmune Therapeutics to Participate in Three Investor Conferences in September
  8. Aimmune Therapeutics to Present at the 2017 Wedbush PacGrow Healthcare Conference on Wednesday, August 16th
  9. Aimmune Therapeutics reports 2Q loss
  10. Aimmune Therapeutics Announces Second Quarter 2017 Financial Results
  11. Aimmune Therapeutics’ Investigational Treatment for Peanut Allergy Featured in Science Translational Medicine Publication on Discovery of New TH2 Cell Subset Specific to Allergy
  12. AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%
  13. Aimmune Therapeutics Enrolls First Patient in ARTEMIS (ARC010) European Phase 3 Clinical Trial of AR101 for the Treatment of Peanut Allergy
  14. Aimmune Therapeutics (AIMT) Shares March Higher, Can It Continue?
  15. Dynavax Technologies (DVAX) Catches Eye: Stock Gains 6.6%
  16. Aimmune Therapeutics Presents European Phase 3 PALISADE Screening Data at 2017 European Academy of Allergy and Clinical Immunology (EAACI) Congress
  17. Aimmune Therapeutics to Present Data on Peanut Allergy in Europe at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2017
  18. Aimmune Therapeutics Reports on Up-Dosing in Its Ongoing Phase 3 PALISADE Trial of AR101 for Peanut Allergy
  19. Aimmune Therapeutics to Present at the Goldman Sachs 38th Annual Global Healthcare Conference on Thursday, June 15th

SEC Filings

  1. 8-K - Current report 171138966
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 171015047
  3. 8-K - Current report 171014863
  4. 8-K - Current report 17916872
  5. 8-K - Current report 17874181
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 17822411
  7. 8-K - Current report 17822321
  8. CT ORDER - Confidential treatment order 17755886
  9. 8-K - Current report 17761437
  10. DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material 17758032